OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Grivas on Sacituzumab Govitecan Plus Pembrolizumab in Metastatic Urothelial Cancer

May 24th 2023

Petros Grivas, MD, PhD, discusses findings from the primary analysis of cohort 3 of the phase 2 TROPHY U-01 trial in patients with metastatic urothelial cancer.

Dr Tsao on the Role of Nivolumab Plus Cabozantinib in Advanced RCC

May 24th 2023

Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.

​​Dr Fallon on Guidelines for the Administration of Infection Prophylaxis in R/R Multiple Myeloma

May 24th 2023

Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.

Dr Zhang on the Rationale for Investigating Sintilimab/Axitinib in FH-Deficient RCC

May 23rd 2023

Xingming Zhang, MD, discusses the rationale for investigating the combination of sintilimab and axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma in a phase 2 trial.

Dr Skoulidis on the Methods of Analyzing KRAS G12C Inhibitor Efficacy in NSCLC

May 23rd 2023

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the methods utilized in a retrospective study that investigated molecular determinants of KRAS G12C inhibitor efficacy in patients with advanced non–small cell lung cancer.

Dr Phillips on the Implications of the FDA Approval of Pirtobrutinib in R/R Mantle Cell Lymphoma

May 23rd 2023

Tycel Phillips, MD, MPH, discusses the implications of the FDA approval of pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr Katims on Characterizing Immune Phenotype in FGFR3-mutated Upper Tract Urothelial Carcinoma

May 23rd 2023

Andrew Katims, MD, MPH, discusses research characterizing immune responses in the tumor microenvironment of FGFR3-mutated upper tract urothelial carcinoma using single-cell RNA-sequencing

Dr Kin on Clinical Implications of the FDA Approval of Teclistamab in R/R Multiple Myeloma

May 23rd 2023

Andrew Kin, MD, discusses clinical implications of the FDA approval for teclistamab-cqyv in relapsed/refractory multiple myeloma.

Dr Harding on the Rationale for Targeting FGFR2 in Cholangiocarcinoma and Biliary Tract Cancers

May 23rd 2023

James Harding, MD, discusses the rationale for targeting FGFR2 in patients with cholangiocarcinoma and biliary tract cancers.

Dr Cardin on Targeting KRAS in Pancreatic Cancer

May 22nd 2023

Dana B Cardin, MD, MSCI, discusses the rationale for exploring KRAS as a therapeutic target in pancreatic cancer.

Dr Phillips on Treatment After Progression on a BTK Inhibitor in MCL

May 22nd 2023

Tycel Phillips, MD, MPH, discusses treatment options for patients with relapsed/refractory mantle cell lymphoma who have progressed on covalent BTK inhibitors.

Dr Srour on the Mechanism of Action of ALLO-316 in Metastatic Clear Cell RCC

May 22nd 2023

Samer A. Srour, MB ChB, MS, discusses the mechanism of action of ALLO-316, which is being investigated for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma, and details safety findings from the phase 1 TRAVERSE study evaluating ALLO-316 in this patient population.

Dr Grieb on the Importance of Targeting the MYC Oncogene in CRC and Solid Tumors

May 22nd 2023

Brian C. Grieb, MD, PhD, emphasizes the importance of investigating agents that target the MYC oncogene, as well as supportive cofactors, in colorectal cancer and other tumor types.

Dr Tauro on Next Steps for the Investigation of Novel Autophagy Inhibitors in R/R Multiple Myeloma

May 22nd 2023

Marilena Tauro, PhD, discusses next steps planned for the development of novel autophagy inhibitory strategies to combat chemotherapy resistance in relapsed/refractory multiple myeloma.

Dr Cummings on Adjuvant Osimertinib in EGFR-Mutant NSCLC

May 19th 2023

Amy L. Cummings, MD, PhD, discusses key findings from the phase 3 ADAURA trial in patients with non–small cell lung cancer harboring EGFR mutations.

Dr Mohan on CAR T-cell Therapies and Bispecific Antibodies in R/R Multiple Myeloma

May 19th 2023

Meera Mohan, MD, MS, FACP, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Dr Hilton on the Impact of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 19th 2023

Christie J. Hilton, DO, discusses the impact of trastuzumab deruxtecan on the treatment of patients with HER2-positive metastatic breast cancer and ongoing research with the agent in this patient population.

Dr Dhanji on Hypertension as a Risk Factor for Mortality in Urothelial Cancer

May 19th 2023

Sohail Dhanji, MD, discusses the investigation of preoperative hypertension as a risk factor in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, as well as other risk factors for mortality in this patient population.

Dr Stone on the Association of Language Barriers and PSA Screening for Prostate Cancer

May 19th 2023

Benjamin V. Stone, MD, discusses the association between language barriers and prostate-specific antigen screening rates in American men.

Dr Rini on the OPTIC RCC Trial in Advanced Kidney Cancer

May 19th 2023

Brian I. Rini, MD, FASCO, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial.

NEXT PAGE
PREVIOUS PAGE